While early-generation FASN inhibitors demonstrated potential efficacy for tumor growth restriction in preclinical breast cancer models, their clinical translation was limited due to substantial toxicity observed in both animal models and human trials [16]. The gene discussed is FASN; the disease is breast carcinoma.